相关实验视频

Updated: May 12, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

在TNBC中,GPX3通过操纵ROS-TGFB1-ZEB2来促进青的耐药性

Qingyi Hu¹, Qianzhi Chen¹, Wen Yang¹

¹Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Cell communication and signaling : CCS

|July 27, 2025

概括

这项研究确定GPX3是三阴性乳腺癌 (TNBC) 中抗性的关键驱动因素. 向GPX3可能会克服耐药性,并改善TNBC患者的治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

三重阴性乳腺癌 (TNBC) 是一个重大的全球健康挑战,原因是有限的有效疗法和高收购耐药率.
基于的化疗是一种常见的治疗方法,但TNBC的耐药性机制需要紧急调查,以确定新的治疗点.

研究的目的:

调查GPX3在TNBC中抗性的作用.
阐明参与GPX3-介导抗性和上皮-介质细胞转换 (EMT) 的信号通路.

主要方法:

在TNBC细胞系中比较GPX3表达,思丁敏感性和ROS生成.
利用RNA测序,生物信息学,西方抹杀,RNA干扰和老鼠异种移植模型.
在临床乳腺癌样本和TCGA数据库中分析了GPX3,TGFB1和ZEB2相关性.

主要成果:

GPX3的上调促进了西斯普拉丁耐药性,并与TNBC细胞的侵入性增加有关.
GPX3-TGFB1-ZEB2轴通过EMT驱动白金电阻和转移.
GPX3的枯竭增强了的敏感性,而它的淘汰抑制了瘤的生长.

结论:

通过GPX3-TGFB1-ZEB2通路,GPX3是TNBC中获得抗性和EMT的关键调解者.
GPX3代表了一个有前途的生物标志物和治疗目标,用于改善高风险TNBC患者的诊断,治疗和预后.

关键词:

化学抗药性化学抗药性是一种抗药性.西斯普拉丁 (Cisplatin) 是一种三阴性乳腺癌是三阴性乳腺癌.

更多相关视频

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...